BRONCUS-B (02216) announced that its BroncTarget® Lung-Targeted Denervation Radiofrequency Ablation System (referred to as the "BroncTarget® System") has officially entered the Special Review Process for Innovative Medical Devices of China's National Medical Products Administration (NMPA). This designation, indicated in the NMPA's public disclosure document under the product name "Lung Radiofrequency Ablation System," signifies that the product's core technological originality and significant clinical value have been recognized by the national medical products regulatory authority. Lung-Targeted Denervation (TLD) is a breakthrough interventional technology for moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It delivers radiofrequency energy precisely to neural targets via a bronchoscope, aiming to fundamentally suppress abnormal airway constriction and mucus hypersecretion, thereby alleviating symptoms such as cough, sputum production, and dyspnea. This technology complements conventional drug therapy as part of an integrated "intervention + medication" management strategy, offering a new direction particularly for patients whose symptoms remain poorly controlled after standard drug treatment. The BroncTarget® System innovatively incorporates designs such as a circular multi-electrode array, an adjustable loop opening, differentiated radiofrequency energy output, real-time temperature and impedance monitoring and control, and intelligent cold saline perfusion, ensuring both the efficiency and safety of the radiofrequency ablation procedure. Currently, the confirmatory clinical trial for the BroncTarget® System is progressing in an orderly manner, with 28 hospitals across the country simultaneously advancing patient recruitment.